
|Articles|March 1, 2006
- Volume 0 0
NCPA IDENTIFIES PRIORITIES
Advertisement
The National Community PharmacistsAssociation (NCPA) is fighting against thecommoditization of pharmacy, the marginalizationof pharmacists as front-line healthcare providers, and the concentration ofpower over the pharmacy benefit in thehands of third-party intermediaries. Therefore,NCPA is directing its resources to focuson fundamental priorities that will protectthe long-term interests of pharmacists andbegin to redefine the pharmacy profession.The priorities include the following:
- Enlisting and leveraging the grass-rootspower of >24,000 independent pharmacists
- Demonstrating the value of pharmacistsin the health care delivery system
- Enacting HR-1671, the pharmacynegotiation bill, to create a level playingfield for pharmacists by allowingthem to negotiate with pharmacybenefit managers
- Working with state governments torecognize the value of pharmacists andguarantee fair compensation for theirprofessional services so that patientscontinue to have access to medicationand to community pharmacists
- Lobbying for legislative amendments tothe Medicare Part D prescription drugprogram
- Encouraging broad adoption by communitypharmacies of electronic prescribingtechnology
Articles in this issue
over 20 years ago
British Poll Shows People Denying Weight Problemsover 20 years ago
Suing a Lawyer for Malpractice?over 20 years ago
Pharmacists—Cops or Not? (Part 1)over 20 years ago
Can You Read These Rxs?over 20 years ago
Alternative Measures for Treating Pediculosisover 20 years ago
Compounding Hotlineover 20 years ago
Obesity May Lead to Kidney Failureover 20 years ago
Body Fat Associated with Alzheimer's Proteinover 20 years ago
Midlife Obesity May Cause Heart Diseaseover 20 years ago
The Evolution of Imprint IdentificationAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Cyclosporiasis Cases Reach 5100: Investigators Zero In On Lettuce, Possible Taco Bell Link
2
Gedatolisib Combination Approved for PIK3CA Wild-Type HR+, HER2– Breast Cancer
3
Subcutaneous Olanzapine in Schizophrenia: Expanding the Utility of a Proven Therapy
4
Anemia in Multiple Myeloma: Mechanisms, Management, and Emerging Therapies
5










































































































